Drug Profile
Teprasiran - Quark-Pharmaceuticals
Alternative Names: AKIi-5; DGFi; I-5NP; QPI-1002; QPI002; Teprasiran sodiumLatest Information Update: 30 Jul 2021
Price :
$50
*
At a glance
- Originator Quark Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action RNA interference; Tumour suppressor protein p53 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Acute kidney injury; Delayed graft function
Most Recent Events
- 08 Jan 2019 Quark Pharmaceuticals completes the phase III ReGIFT trial in Delayed graft function (Prevention) in USA, Spain, Czech Republic, Belgium, Netherlands, Argentina, Australia, Brazil, Canada, France and Germany (IV) (NCT02610296)
- 25 May 2018 Phase-III clinical trials in Acute kidney injury (Prevention, In adults, In the elderly) in USA (IV) (NCT03510897)
- 27 Apr 2018 Quark Pharmaceuticals plans the MAKE phase III trial for Acute Kidney Injury in May 2018 , (NCT03510897)